Cagrilintide is an experimental analog of amylin, a pancreatic hormone that plays a role in controlling satiety and regulating body weight. The peptide has been developed as an agonist of amylin receptors (AMY) and calcitonin receptors, and it has demonstrated remarkable effects in studies for the treatment of obesity and metabolic disorders.

Unlike other peptide drugs that target only GLP-1, cagrilintide acts on complementary pathways in the central nervous system to reduce calorie intake and delay gastric emptying. Its efficacy when used alone or in combination with other incretin mimetics has been extensively studied.